Skip to main content

Advertisement

Table 2 Characterization of NPs

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

  Size (nm) Zeta (mV) PDI DEE (%) DLC (%)
Blank-NPs 106.70 ± 1.72 −32.9 ± 1.23 0.104 ± 0.015
LFC-Blank-NPs 124.30 ± 2.22 −14.80 ± 2.06 0.120 ± 0.022
Sora-NPs 112.37 ± 2.89 −33.13 ± 1.17 0.106 ± 0.027 54.82 ± 6.46 1.09 ± 0.13
LFC-Sora-NPs 145.10 ± 2.08 −15.47 ± 2.44 0.113 ± 0.012 52.17 ± 3.92 1.03 ± 0.07
Meta-NPs 114.80 ± 2.70 −32.80 ± 2.40 0.135 ± 0.030 63.31 ± 12.75 1.27 ± 0.27
LFC-Meta-NPs 147.10 ± 0.92 −17.80 ± 1.41 0.123 ± 0.065 61.34 ± 19.40 1.23 ± 0.34
  1. Data are expressed as the mean ± SD (n = 3)